Regeneron Pharmaceuticals Thursday reported better-than-expected second quarter earnings of $5.45 per share on a revenue of $1.6 billion. Revenue for the quarter rose 9% year-over-year driven by strong US sales growth of Eylea and Dupixent drugs. On a GAAP basis, net income jumped 44% to $4.82 per share. In the US, Eylea sales grew 8% … Continue reading Eylea lifts Regeneron Q2 earnings